<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04802707</url>
  </required_header>
  <id_info>
    <org_study_id>2021-7654 dC-dT-MDS</org_study_id>
    <nct_id>NCT04802707</nct_id>
  </id_info>
  <brief_title>Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome</brief_title>
  <acronym>dC-dT-MDS</acronym>
  <official_title>A Phase II, Monocenter, Single Arm Study To Assess The Safety and Efficacy Of Combination Deoxycytidine and Deoxythymidine For Mitochondrial Depletion Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Centre/Research Institute of the McGill University Health Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Centre/Research Institute of the McGill University Health Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a genetically and clinically&#xD;
      heterogeneous group of autosomal recessive disorders that are characterized by a severe&#xD;
      reduction in mtDNA content leading to impaired energy production in affected tissues and&#xD;
      organs. MDS are due to defects in mtDNA maintenance caused by mutations in nuclear genes that&#xD;
      function in either mitochondrial nucleotide synthesis. MDS are phenotypically heterogeneous&#xD;
      and usually classified as myopathic, encephalomyopathic, hepatocerebral or&#xD;
      neurogastrointestinal.&#xD;
&#xD;
      No efficacious therapy is available for any of these disorders. Affected individuals should&#xD;
      have a comprehensive evaluation to assess the degree of involvement of different systems.&#xD;
      Treatment is directed mainly toward providing symptomatic management. No treatment for MDS.&#xD;
&#xD;
      Clinical trials studies and in vitro/in vivo research studies showed that the enhancement of&#xD;
      the salvage pathway by increasing the availability of deoxyribonucleosides needed for each&#xD;
      specific genetic defect prevents mtDNA depletion.&#xD;
&#xD;
      Early recognition and immediate therapy to restore mitochondrial function could potentially&#xD;
      improve clinical course.&#xD;
&#xD;
      Confirming the benefit of deoxynucleosides as a safe and potentially efficacious therapy,&#xD;
      will lead to the availability of the first specific and effective treatment for Mitochondria&#xD;
      Depletion Disorders.&#xD;
&#xD;
      In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and&#xD;
      Deoxythymidine dT) will be used as early treatment of MDS.&#xD;
&#xD;
      The dose used has been already used in other clinical trials, and appears to effective and&#xD;
      well-tolerated. The subjects included are children (0-18Y), with positive MDS diagnosis and&#xD;
      express mutations in one of the following genes: POLG, C10orf2, TYMP, RRM2B, MPV17, SUCLA2,&#xD;
      SUCLG1, FBXL4. Subjects with MDS expressing neurological phenotypes dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Trial is designed as Phase II, Monocenter, Open label study in the pediatric population.&#xD;
&#xD;
      The aim is to evaluate the safety, tolerability and efficacy of Deoxycytidine and&#xD;
      Deoxythymidine in treatment of children with Mitochondrial Depletion Disorders.&#xD;
&#xD;
      Primary Objectives The primary objective of this study is to evaluate the efficacy of&#xD;
      dC/dT100-400 in subjects with mitochondria depletion disorders.&#xD;
&#xD;
      Secondary Objectives The secondary objectives of this study are to evaluate tolerability and&#xD;
      safety of dC/dT100-400 in subjects with mitochondria depletion disorders.&#xD;
&#xD;
      First Outcome&#xD;
&#xD;
      Efficacy of dC/dT100-400 :&#xD;
&#xD;
        1. Neurological improvement by electroencephalography (EEG), seizure diary, development and&#xD;
           quality of life, clinical status observed during the neurological follow-up.&#xD;
&#xD;
        2. Improved clinical status observed during the genetic follow-up and the Newcastle&#xD;
           Paediatric Mitochondrial Disease Scale (NPMDS), which are forms used by geneticist to&#xD;
           allow evaluation of the progression of mitochondrial disease in patients less than 18&#xD;
           years of age.&#xD;
&#xD;
        3. Bloodwork for different assessments:&#xD;
&#xD;
      liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT),&#xD;
      gamma-glutamyl transferase (GGT), bilirubin and albumin.), kidney function (creatinine, urea,&#xD;
      electrolytes). Assess for myopathy with serum creatine kinase (CK). Evaluation of&#xD;
      mitochondrial function with capillary/venous blood gas, serum lactate, plasma amino acids,&#xD;
      acylcarnitine profile, urine amino acids, urine purines and pyrimidines acids, and growth&#xD;
      differentiation factor 15 (GDF15; a marker of severity of mitochondria dysfunction).&#xD;
&#xD;
      Secondary Outcome&#xD;
&#xD;
      - Safety and tolerability will be tested by recording adverse effects (AE): AE will be&#xD;
      monitored and collected throughout the study.&#xD;
&#xD;
        1. Diarrhea: Reported diarrhea frequency during the treatment, will permit to define the&#xD;
           tolerability of dC/dT100-400.&#xD;
&#xD;
        2. AE leading to study drug discontinuation, treatment-emergent adverse events (TEAEs),&#xD;
           SAEs (Severe Adverse Effect) will be reported from the first day the subjects start&#xD;
           taking medication until the last dose taken.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II, One Site, Open label study in the pediatric population</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Responder versus Non-Responder Status with investigational product</measure>
    <time_frame>26 weeks</time_frame>
    <description>&quot;Responder&quot; defined as having ≥ 2 of (1) electroencephalography EEG improvement, (2) decreased seizure frequency, (3) cognitive improvement, (4) caregiver impression of improvement, (5) clinical improvement, (6) Normal Organics and Metabolism functions Description of the primary variable(s) The primary efficacy endpoint is the composite cluster of the first occurrence, over the duration of study, of Mitochondria Depletion Syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing dose-limiting toxicities, adverse events (AEs), serious adverse events (SAEs)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Safety profile will be assessed through number of participants experiencing adverse events (AEs), serious adverse events (SAEs), laboratory evaluations, vital signs, and physical examinations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mitochondrial Diseases</condition>
  <condition>Mitochondrial Encephalomyopathy</condition>
  <condition>Mitochondrial Encephalopathy</condition>
  <condition>Mitochondrial DNA Depletion</condition>
  <condition>Mitochondrial Metabolism Disorders</condition>
  <arm_group>
    <arm_group_label>dC/dT100-400 Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children 0-18 Y who takes the investigational product deoxynucleosides pyrimidine (mix of deoxycytidine and deoxythymidine), following the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>deoxycytidine and deoxythymidine</intervention_name>
    <description>The Investigational Product (IP) dC/dT100-400 will be administered orally every day (QD) and the dose is divided over 3 taking/day for the daily dose of 100 mg/kg from Day 1-7, 200 mg/kg from Day 8-14, 300 mg/kg from Day 15- 21 and 400 mg/kg from Day 22 to 182. Doses was chosen according to the safety and efficacy doses used in the literature.</description>
    <arm_group_label>dC/dT100-400 Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children 0 -18 Y&#xD;
&#xD;
          -  Written informed consent obtained,&#xD;
&#xD;
          -  Clinical Diagnosis of a Mitochondrial Depletion Disorder.&#xD;
&#xD;
          -  Pathogenic variant(s) in one of the following genes: POLG, C10orf2, TYMP, RRM2B,&#xD;
             MPV17, SUCLA2, SUCLG1, FBXL4&#xD;
&#xD;
          -  Females of childbearing age:&#xD;
&#xD;
        Negative urinary pregnancy test at screening Agree to use effective contraception for the&#xD;
        duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability of a parent or legal guardian to give informed consent for any reason&#xD;
&#xD;
          -  Chronic severe diarrhea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Alexis MD Myers, MD PhD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>RI-MUHC, Children Hospital of Montreal (MUHC), McGill University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth Alexis MD Myers, MD PhD FRCPC</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>23316</phone_ext>
    <email>kenneth.myers@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saoussen Dr Berrahmoune, PhD</last_name>
    <phone>514-934-1934</phone>
    <phone_ext>76204</phone_ext>
    <email>saoussen.berrahmoune@rimuhc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research InstituMcGill University Health Centre - Children Hospital of Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Kenneth Myers, MD</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>76204</phone_ext>
      <email>kenneth.myers@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Saoussen Berrahmoune, PhD</last_name>
      <phone>5149004065</phone>
      <email>saoussen.berrahmoune@rimuhc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Daniela Buhas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Myers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab. 2012 Dec;26(6):711-23. doi: 10.1016/j.beem.2012.05.003. Epub 2012 Jun 23. Review.</citation>
    <PMID>23168274</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller FJ, Rosenfeldt FL, Zhang C, Linnane AW, Nagley P. Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age. Nucleic Acids Res. 2003 Jun 1;31(11):e61.</citation>
    <PMID>12771225</PMID>
  </results_reference>
  <results_reference>
    <citation>DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003 Jun 26;348(26):2656-68. Review.</citation>
    <PMID>12826641</PMID>
  </results_reference>
  <results_reference>
    <citation>Huang CC, Hsu CH. [Mitochondrial disease and mitochondrial DNA depletion syndromes]. Acta Neurol Taiwan. 2009 Dec;18(4):287-95. Review. Chinese.</citation>
    <PMID>20329599</PMID>
  </results_reference>
  <results_reference>
    <citation>Rusecka J, Kaliszewska M, Bartnik E, Tońska K. Nuclear genes involved in mitochondrial diseases caused by instability of mitochondrial DNA. J Appl Genet. 2018 Feb;59(1):43-57. doi: 10.1007/s13353-017-0424-3. Epub 2018 Jan 17. Review.</citation>
    <PMID>29344903</PMID>
  </results_reference>
  <results_reference>
    <citation>Viscomi C, Zeviani M. MtDNA-maintenance defects: syndromes and genes. J Inherit Metab Dis. 2017 Jul;40(4):587-599. doi: 10.1007/s10545-017-0027-5. Epub 2017 Mar 21. Review.</citation>
    <PMID>28324239</PMID>
  </results_reference>
  <results_reference>
    <citation>Blázquez-Bermejo C, Carreño-Gago L, Molina-Granada D, Aguirre J, Ramón J, Torres-Torronteras J, Cabrera-Pérez R, Martín MÁ, Domínguez-González C, de la Cruz X, Lombès A, García-Arumí E, Martí R, Cámara Y. Increased dNTP pools rescue mtDNA depletion in human POLG-deficient fibroblasts. FASEB J. 2019 Jun;33(6):7168-7179. doi: 10.1096/fj.201801591R. Epub 2019 Mar 8.</citation>
    <PMID>30848931</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013 Apr;10(2):186-98. doi: 10.1007/s13311-013-0177-6. Review.</citation>
    <PMID>23385875</PMID>
  </results_reference>
  <results_reference>
    <citation>Nogueira C, Almeida LS, Nesti C, Pezzini I, Videira A, Vilarinho L, Santorelli FM. Syndromes associated with mitochondrial DNA depletion. Ital J Pediatr. 2014 Apr 3;40:34. doi: 10.1186/1824-7288-40-34. Review.</citation>
    <PMID>24708634</PMID>
  </results_reference>
  <results_reference>
    <citation>Basel D. Mitochondrial DNA Depletion Syndromes. Clin Perinatol. 2020 Mar;47(1):123-141. doi: 10.1016/j.clp.2019.10.008. Epub 2019 Oct 31. Review.</citation>
    <PMID>32000920</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child. 2009 Jan;94(1):3-5. doi: 10.1136/adc.2008.147983.</citation>
    <PMID>19103785</PMID>
  </results_reference>
  <results_reference>
    <citation>Spinazzola A, Invernizzi F, Carrara F, Lamantea E, Donati A, Dirocco M, Giordano I, Meznaric-Petrusa M, Baruffini E, Ferrero I, Zeviani M. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis. 2009 Apr;32(2):143-58. doi: 10.1007/s10545-008-1038-z. Epub 2008 Dec 27.</citation>
    <PMID>19125351</PMID>
  </results_reference>
  <results_reference>
    <citation>Suomalainen A, Isohanni P. Mitochondrial DNA depletion syndromes--many genes, common mechanisms. Neuromuscul Disord. 2010 Jul;20(7):429-37. doi: 10.1016/j.nmd.2010.03.017. Epub 2010 May 4. Review.</citation>
    <PMID>20444604</PMID>
  </results_reference>
  <results_reference>
    <citation>Copeland WC. Defects in mitochondrial DNA replication and human disease. Crit Rev Biochem Mol Biol. 2012 Jan-Feb;47(1):64-74. doi: 10.3109/10409238.2011.632763. Review.</citation>
    <PMID>22176657</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan NA, Govindaraj P, Meena AK, Thangaraj K. Mitochondrial disorders: challenges in diagnosis &amp; treatment. Indian J Med Res. 2015 Jan;141(1):13-26. Review.</citation>
    <PMID>25857492</PMID>
  </results_reference>
  <results_reference>
    <citation>Hikmat O, Eichele T, Tzoulis C, Bindoff LA. Understanding the Epilepsy in POLG Related Disease. Int J Mol Sci. 2017 Aug 24;18(9). pii: E1845. doi: 10.3390/ijms18091845. Review.</citation>
    <PMID>28837072</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Hattab AW, Craigen WJ, Scaglia F. Mitochondrial DNA maintenance defects. Biochim Biophys Acta Mol Basis Dis. 2017 Jun;1863(6):1539-1555. doi: 10.1016/j.bbadis.2017.02.017. Epub 2017 Feb 16. Review.</citation>
    <PMID>28215579</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Hattab, A.W., et al., Mitochondrial DNA Maintenance Defects Overview, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>Copeland WC. Defects of mitochondrial DNA replication. J Child Neurol. 2014 Sep;29(9):1216-24. doi: 10.1177/0883073814537380. Epub 2014 Jun 30. Review.</citation>
    <PMID>24985751</PMID>
  </results_reference>
  <results_reference>
    <citation>Spinazzola A, Zeviani M. Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J Intern Med. 2009 Feb;265(2):174-92. doi: 10.1111/j.1365-2796.2008.02059.x.</citation>
    <PMID>19192035</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen, B.H., P.F. Chinnery, and W.C. Copeland, POLG-Related Disorders, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>Milone M, Benarroch EE, Wong LJ. POLG-related disorders: defects of the nuclear and mitochondrial genome interaction. Neurology. 2011 Nov 15;77(20):1847-52. doi: 10.1212/WNL.0b013e318238863a. Review.</citation>
    <PMID>22084276</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat Rev Neurol. 2019 Jan;15(1):40-52. doi: 10.1038/s41582-018-0101-0. Review.</citation>
    <PMID>30451971</PMID>
  </results_reference>
  <results_reference>
    <citation>Anagnostou ME, Ng YS, Taylor RW, McFarland R. Epilepsy due to mutations in the mitochondrial polymerase gamma (POLG) gene: A clinical and molecular genetic review. Epilepsia. 2016 Oct;57(10):1531-1545. doi: 10.1111/epi.13508. Epub 2016 Aug 24. Review.</citation>
    <PMID>27554452</PMID>
  </results_reference>
  <results_reference>
    <citation>Engelsen BA, Tzoulis C, Karlsen B, Lillebø A, Laegreid LM, Aasly J, Zeviani M, Bindoff LA. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain. 2008 Mar;131(Pt 3):818-28. doi: 10.1093/brain/awn007. Epub 2008 Jan 30.</citation>
    <PMID>18238797</PMID>
  </results_reference>
  <results_reference>
    <citation>Horvath R, Hudson G, Ferrari G, Fütterer N, Ahola S, Lamantea E, Prokisch H, Lochmüller H, McFarland R, Ramesh V, Klopstock T, Freisinger P, Salvi F, Mayr JA, Santer R, Tesarova M, Zeman J, Udd B, Taylor RW, Turnbull D, Hanna M, Fialho D, Suomalainen A, Zeviani M, Chinnery PF. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain. 2006 Jul;129(Pt 7):1674-84. Epub 2006 Apr 18.</citation>
    <PMID>16621917</PMID>
  </results_reference>
  <results_reference>
    <citation>Hikmat O, Tzoulis C, Chong WK, Chentouf L, Klingenberg C, Fratter C, Carr LJ, Prabhakar P, Kumaraguru N, Gissen P, Cross JH, Jacques TS, Taanman JW, Bindoff LA, Rahman S. Correction: The clinical spectrum and natural history of early-onset diseases due to DNA polymerase gamma mutations. Genet Med. 2019 Apr;21(4):1027. doi: 10.1038/s41436-018-0098-1.</citation>
    <PMID>30228318</PMID>
  </results_reference>
  <results_reference>
    <citation>Lim A, Thomas RH. The mitochondrial epilepsies. Eur J Paediatr Neurol. 2020 Jan;24:47-52. doi: 10.1016/j.ejpn.2019.12.021. Epub 2020 Jan 7. Review.</citation>
    <PMID>31973983</PMID>
  </results_reference>
  <results_reference>
    <citation>Ashley N, Adams S, Slama A, Zeviani M, Suomalainen A, Andreu AL, Naviaux RK, Poulton J. Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances. Hum Mol Genet. 2007 Jun 15;16(12):1400-11. Epub 2007 May 3.</citation>
    <PMID>17483096</PMID>
  </results_reference>
  <results_reference>
    <citation>Gandhi VV, Samuels DC. A review comparing deoxyribonucleoside triphosphate (dNTP) concentrations in the mitochondrial and cytoplasmic compartments of normal and transformed cells. Nucleosides Nucleotides Nucleic Acids. 2011 May;30(5):317-39. doi: 10.1080/15257770.2011.586955. Review.</citation>
    <PMID>21774628</PMID>
  </results_reference>
  <results_reference>
    <citation>González-Vioque E, Torres-Torronteras J, Andreu AL, Martí R. Limited dCTP availability accounts for mitochondrial DNA depletion in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). PLoS Genet. 2011 Mar;7(3):e1002035. doi: 10.1371/journal.pgen.1002035. Epub 2011 Mar 31.</citation>
    <PMID>21483760</PMID>
  </results_reference>
  <results_reference>
    <citation>Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant resulting from mitochondrial DNA depletion. Pediatr Neurol. 2001 Jan;24(1):60-3.</citation>
    <PMID>11182283</PMID>
  </results_reference>
  <results_reference>
    <citation>Keshavan N, Abdenur J, Anderson G, Assouline Z, Barcia G, Bouhikbar L, Chakrapani A, Cleary M, Cohen MC, Feillet F, Fratter C, Hauser N, Jacques T, Lam A, McCullagh H, Phadke R, Rötig A, Sharrard M, Simon M, Smith C, Sommerville EW, Taylor RW, Yue WW, Rahman S. The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency. Genet Med. 2020 Jan;22(1):199-209. doi: 10.1038/s41436-019-0613-z. Epub 2019 Aug 29.</citation>
    <PMID>31462754</PMID>
  </results_reference>
  <results_reference>
    <citation>Shaibani A, Shchelochkov OA, Zhang S, Katsonis P, Lichtarge O, Wong LJ, Shinawi M. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol. 2009 Aug;66(8):1028-32. doi: 10.1001/archneurol.2009.139.</citation>
    <PMID>19667227</PMID>
  </results_reference>
  <results_reference>
    <citation>Bourdon A, Minai L, Serre V, Jais JP, Sarzi E, Aubert S, Chrétien D, de Lonlay P, Paquis-Flucklinger V, Arakawa H, Nakamura Y, Munnich A, Rötig A. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007 Jun;39(6):776-80. Epub 2007 May 7.</citation>
    <PMID>17486094</PMID>
  </results_reference>
  <results_reference>
    <citation>Kollberg G, Darin N, Benan K, Moslemi AR, Lindal S, Tulinius M, Oldfors A, Holme E. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord. 2009 Feb;19(2):147-50. doi: 10.1016/j.nmd.2008.11.014. Epub 2009 Jan 12.</citation>
    <PMID>19138848</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Hattab, A.W., et al., MPV17-Related Mitochondrial DNA Maintenance Defect, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>El-Hattab AW, Wang J, Dai H, Almannai M, Staufner C, Alfadhel M, Gambello MJ, Prasun P, Raza S, Lyons HJ, Afqi M, Saleh MAM, Faqeih EA, Alzaidan HI, Alshenqiti A, Flore LA, Hertecant J, Sacharow S, Barbouth DS, Murayama K, Shah AA, Lin HC, Wong LC. MPV17-related mitochondrial DNA maintenance defect: New cases and review of clinical, biochemical, and molecular aspects. Hum Mutat. 2018 Apr;39(4):461-470. doi: 10.1002/humu.23387. Epub 2018 Jan 13.</citation>
    <PMID>29282788</PMID>
  </results_reference>
  <results_reference>
    <citation>El-Hattab, A.W. and F. Scaglia, SUCLA2-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form with Methylmalonic Aciduria, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>El-Hattab, A.W. and F. Scaglia, SUCLG1-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form with Methylmalonic Aciduria, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>Almannai, M., et al., FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome, in GeneReviews((R)), M.P. Adam, et al., Editors. 1993: Seattle (WA).</citation>
  </results_reference>
  <results_reference>
    <citation>Saada A. Deoxyribonucleotides and disorders of mitochondrial DNA integrity. DNA Cell Biol. 2004 Dec;23(12):797-806. Review.</citation>
    <PMID>15684706</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang L. Mitochondrial purine and pyrimidine metabolism and beyond. Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):578-594. Review.</citation>
    <PMID>27906631</PMID>
  </results_reference>
  <results_reference>
    <citation>Akanuma J. [Mitochondrial DNA depletion syndrome]. Nihon Rinsho. 2002 Apr;60 Suppl 4:398-401. Review. Japanese.</citation>
    <PMID>12013896</PMID>
  </results_reference>
  <results_reference>
    <citation>Zipursky A. The genetics of childhood disease and development. Pediatr Res. 2003 Jan;53(1):3.</citation>
    <PMID>12508073</PMID>
  </results_reference>
  <results_reference>
    <citation>Filosto M, Scarpelli M, Tonin P, Lucchini G, Pavan F, Santus F, Parini R, Donati MA, Cotelli MS, Vielmi V, Todeschini A, Canonico F, Tomelleri G, Padovani A, Rovelli A. Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. J Neurol. 2012 Dec;259(12):2699-706. doi: 10.1007/s00415-012-6572-9. Epub 2012 Jun 19.</citation>
    <PMID>22711161</PMID>
  </results_reference>
  <results_reference>
    <citation>Hirano M, Martí R, Casali C, Tadesse S, Uldrick T, Fine B, Escolar DM, Valentino ML, Nishino I, Hesdorffer C, Schwartz J, Hawks RG, Martone DL, Cairo MS, DiMauro S, Stanzani M, Garvin JH Jr, Savage DG. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology. 2006 Oct 24;67(8):1458-60. Epub 2006 Sep 13.</citation>
    <PMID>16971696</PMID>
  </results_reference>
  <results_reference>
    <citation>Yavuz H, Ozel A, Christensen M, Christensen E, Schwartz M, Elmaci M, Vissing J. Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol. 2007 Mar;64(3):435-8.</citation>
    <PMID>17353390</PMID>
  </results_reference>
  <results_reference>
    <citation>Hasselmann O, Blau N, Ramaekers VT, Quadros EV, Sequeira JM, Weissert M. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol Genet Metab. 2010 Jan;99(1):58-61. doi: 10.1016/j.ymgme.2009.08.005.</citation>
    <PMID>19766516</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodriguez MC, MacDonald JR, Mahoney DJ, Parise G, Beal MF, Tarnopolsky MA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007 Feb;35(2):235-42.</citation>
    <PMID>17080429</PMID>
  </results_reference>
  <results_reference>
    <citation>Saito K, Kimura N, Oda N, Shimomura H, Kumada T, Miyajima T, Murayama K, Tanaka M, Fujii T. Pyruvate therapy for mitochondrial DNA depletion syndrome. Biochim Biophys Acta. 2012 May;1820(5):632-6. doi: 10.1016/j.bbagen.2011.08.006. Epub 2011 Aug 11.</citation>
    <PMID>21855607</PMID>
  </results_reference>
  <results_reference>
    <citation>Wong LJ, Naviaux RK, Brunetti-Pierri N, Zhang Q, Schmitt ES, Truong C, Milone M, Cohen BH, Wical B, Ganesh J, Basinger AA, Burton BK, Swoboda K, Gilbert DL, Vanderver A, Saneto RP, Maranda B, Arnold G, Abdenur JE, Waters PJ, Copeland WC. Molecular and clinical genetics of mitochondrial diseases due to POLG mutations. Hum Mutat. 2008 Sep;29(9):E150-72. doi: 10.1002/humu.20824.</citation>
    <PMID>18546365</PMID>
  </results_reference>
  <results_reference>
    <citation>Lara MC, Valentino ML, Torres-Torronteras J, Hirano M, Martí R. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): biochemical features and therapeutic approaches. Biosci Rep. 2007 Jun;27(1-3):151-63. Review.</citation>
    <PMID>17549623</PMID>
  </results_reference>
  <results_reference>
    <citation>Lara MC, Weiss B, Illa I, Madoz P, Massuet L, Andreu AL, Valentino ML, Anikster Y, Hirano M, Martí R. Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology. 2006 Oct 24;67(8):1461-3. Epub 2006 Sep 13.</citation>
    <PMID>16971699</PMID>
  </results_reference>
  <results_reference>
    <citation>Cámara Y, González-Vioque E, Scarpelli M, Torres-Torronteras J, Martí R. Feeding the deoxyribonucleoside salvage pathway to rescue mitochondrial DNA. Drug Discov Today. 2013 Oct;18(19-20):950-7. doi: 10.1016/j.drudis.2013.06.009. Epub 2013 Jun 28. Review.</citation>
    <PMID>23817075</PMID>
  </results_reference>
  <results_reference>
    <citation>Uusimaa J, Evans J, Smith C, Butterworth A, Craig K, Ashley N, Liao C, Carver J, Diot A, Macleod L, Hargreaves I, Al-Hussaini A, Faqeih E, Asery A, Al Balwi M, Eyaid W, Al-Sunaid A, Kelly D, van Mourik I, Ball S, Jarvis J, Mulay A, Hadzic N, Samyn M, Baker A, Rahman S, Stewart H, Morris AA, Seller A, Fratter C, Taylor RW, Poulton J. Clinical, biochemical, cellular and molecular characterization of mitochondrial DNA depletion syndrome due to novel mutations in the MPV17 gene. Eur J Hum Genet. 2014 Feb;22(2):184-91. doi: 10.1038/ejhg.2013.112. Epub 2013 May 29.</citation>
    <PMID>23714749</PMID>
  </results_reference>
  <results_reference>
    <citation>Dalla Rosa I, Cámara Y, Durigon R, Moss CF, Vidoni S, Akman G, Hunt L, Johnson MA, Grocott S, Wang L, Thorburn DR, Hirano M, Poulton J, Taylor RW, Elgar G, Martí R, Voshol P, Holt IJ, Spinazzola A. MPV17 Loss Causes Deoxynucleotide Insufficiency and Slow DNA Replication in Mitochondria. PLoS Genet. 2016 Jan 13;12(1):e1005779. doi: 10.1371/journal.pgen.1005779. eCollection 2016 Jan.</citation>
    <PMID>26760297</PMID>
  </results_reference>
  <results_reference>
    <citation>Bulst S, Holinski-Feder E, Payne B, Abicht A, Krause S, Lochmüller H, Chinnery PF, Walter MC, Horvath R. In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. Mol Genet Metab. 2012 Sep;107(1-2):95-103. doi: 10.1016/j.ymgme.2012.04.022. Epub 2012 May 3.</citation>
    <PMID>22608879</PMID>
  </results_reference>
  <results_reference>
    <citation>Franzolin E, Salata C, Bianchi V, Rampazzo C. The Deoxynucleoside Triphosphate Triphosphohydrolase Activity of SAMHD1 Protein Contributes to the Mitochondrial DNA Depletion Associated with Genetic Deficiency of Deoxyguanosine Kinase. J Biol Chem. 2015 Oct 23;290(43):25986-96. doi: 10.1074/jbc.M115.675082. Epub 2015 Sep 4.</citation>
    <PMID>26342080</PMID>
  </results_reference>
  <results_reference>
    <citation>Akman HO, Dorado B, López LC, García-Cazorla A, Vilà MR, Tanabe LM, Dauer WT, Bonilla E, Tanji K, Hirano M. Thymidine kinase 2 (H126N) knockin mice show the essential role of balanced deoxynucleotide pools for mitochondrial DNA maintenance. Hum Mol Genet. 2008 Aug 15;17(16):2433-40. doi: 10.1093/hmg/ddn143. Epub 2008 May 8.</citation>
    <PMID>18467430</PMID>
  </results_reference>
  <results_reference>
    <citation>Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010 Jun;51(6):1069-77. doi: 10.1111/j.1528-1167.2009.02397.x. Epub 2009 Nov 3. Erratum in: Epilepsia. 2010 Sep;51(9):1922.</citation>
    <PMID>19889013</PMID>
  </results_reference>
  <results_reference>
    <citation>Domínguez-González C, Madruga-Garrido M, Mavillard F, Garone C, Aguirre-Rodríguez FJ, Donati MA, Kleinsteuber K, Martí I, Martín-Hernández E, Morealejo-Aycinena JP, Munell F, Nascimento A, Kalko SG, Sardina MD, Álvarez Del Vayo C, Serrano O, Long Y, Tu Y, Levin B, Thompson JLP, Engelstad K, Uddin J, Torres-Torronteras J, Jimenez-Mallebrera C, Martí R, Paradas C, Hirano M. Deoxynucleoside Therapy for Thymidine Kinase 2-Deficient Myopathy. Ann Neurol. 2019 Aug;86(2):293-303. doi: 10.1002/ana.25506. Epub 2019 Jun 17.</citation>
    <PMID>31125140</PMID>
  </results_reference>
  <results_reference>
    <citation>Hernandez-Voth A, Sayas Catalan J, Corral Blanco M, Castaño Mendez A, Martin MA, De Fuenmayor Fernandez de la Hoz C, Villena Garrido V, Dominguez-Gonzalez C. Deoxynucleoside therapy for respiratory involvement in adult patients with thymidine kinase 2-deficient myopathy. BMJ Open Respir Res. 2020 Nov;7(1). pii: e000774. doi: 10.1136/bmjresp-2020-000774.</citation>
    <PMID>33246973</PMID>
  </results_reference>
  <results_reference>
    <citation>Purine and pyrimidine metabolism. Ciba Found Symp. 1977;(48):331-55.</citation>
    <PMID>245993</PMID>
  </results_reference>
  <results_reference>
    <citation>Bory C, Chantin C, Boulieu R. Abnormal purine and pyrimidine metabolism in inherited superactivity of PRPP synthetase. Adv Exp Med Biol. 1994;370:15-8.</citation>
    <PMID>7660879</PMID>
  </results_reference>
  <results_reference>
    <citation>Castellanos M, Wilson DB, Shuler ML. A modular minimal cell model: purine and pyrimidine transport and metabolism. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6681-6. Epub 2004 Apr 16.</citation>
    <PMID>15090651</PMID>
  </results_reference>
  <results_reference>
    <citation>Khan I, Sarker SJ, Hackshaw A. Smaller sample sizes for phase II trials based on exact tests with actual error rates by trading-off their nominal levels of significance and power. Br J Cancer. 2012 Nov 20;107(11):1801-9. doi: 10.1038/bjc.2012.444.</citation>
    <PMID>23169334</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Centre/Research Institute of the McGill University Health Centre</investigator_affiliation>
    <investigator_full_name>Kenneth Myers, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Deoxycytidine</keyword>
  <keyword>Deoxythymidine</keyword>
  <keyword>Deoxynucleoside</keyword>
  <keyword>Pyrimidine</keyword>
  <keyword>Mitochondria</keyword>
  <keyword>mtDNA</keyword>
  <keyword>Depletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>REDCap software will be used as IPD. The data's will be shared anonymous, subject will bes identified by an Identifiant (ID).&#xD;
REDCap is managed by quality data's teams of research institute of McGill University Health Center (RI-MUHC).&#xD;
For clinical study reports since the study is planned at the Children Hospital of Montreal, Clinical Study Report (CSR) access will be done through open architecture clinical information system (Oacis) tool of hospital Study Protocol And Informed Consent Form (ICF) will be shared by Email or on core network of RIMUHC</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>26 weeks</ipd_time_frame>
    <ipd_access_criteria>Research Staff, Principal Investigator (PI), Co-Investigator, regulation authority and clinical research associate (CRA) for monitoring are authorized to access to the data's for CRA (anonymous data's)</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

